Unknown

Dataset Information

0

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.


ABSTRACT: Dasatinib inhibits src family kinases and has anti-angiogenic properties. We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC).Patients were enrolled in a dose escalation cohort to establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D). Using a "3?+?3" design, twelve patients with advanced solid tumors received dasatinib (50 mg twice daily or 70 mg daily), capecitabine (850 mg/m(2) twice daily, days 1-14), oxaliplatin (130 mg/m(2) on day 1) and bevacizumab (7.5 mg/kg on day1), every 3 weeks. Ten patients with previously untreated metastatic CRC were then enrolled in an expansion cohort. Activated src (src(act)) expression was measured by immunohistochemistry, using an antibody that selectively recognizes the active conformation of src (clone 28).Twenty-two patients were enrolled between June 2009 and May 2011. Two DLTs were observed in the 50 mg bid dasatinib cohort, and one DLT was observed in the 70 mg daily dasatinib cohort. The MTD and RP2D for dasatinib was 70 mg daily. The most common treatment-related adverse events were fatigue (20; 91 %) and diarrhea (18; 82 %). Biomarker analysis of src(act) expression demonstrated that the overall response rate (ORR) was 75 % (6/8) for patients with high src(act) expression (IHC???2), compared to 0 % (0/8) for patients with low srcact expression (IHC 0 or 1); (p?=?0.007).The RP2D of dasatinib is 70 mg daily in combination with CapeOx/bevacizumab. High levels of srcact expression may predict those patients most likely to benefit from dasatinib.

SUBMITTER: Strickler JH 

PROVIDER: S-EPMC4108590 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Strickler John H JH   McCall Shannon S   Nixon Andrew B AB   Brady John C JC   Pang Herbert H   Rushing Christel C   Cohn Allen A   Starodub Alexander A   Arrowood Christy C   Haley Sherri S   Meadows Kellen L KL   Morse Michael A MA   Uronis Hope E HE   Blobe Gerard C GC   Hsu S David SD   Zafar S Yousuf SY   Hurwitz Herbert I HI  

Investigational new drugs 20131101 2


<h4>Purpose</h4>Dasatinib inhibits src family kinases and has anti-angiogenic properties. We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC).<h4>Methods</h4>Patients were enrolled in a dose escalation cohort to establish the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D). Using a "3 + 3" design, twelve patients with advanced solid tumors received dasatini  ...[more]

Similar Datasets

| S-EPMC11316091 | biostudies-literature
| S-EPMC4618621 | biostudies-literature
| S-EPMC5029686 | biostudies-literature
| S-EPMC3776974 | biostudies-literature
| S-EPMC3607522 | biostudies-literature
| S-EPMC10987514 | biostudies-literature
| S-EPMC7042984 | biostudies-literature
| S-EPMC4106457 | biostudies-literature
| S-EPMC3639662 | biostudies-literature
| S-EPMC7446555 | biostudies-literature